Natera (NTRA)
Health Care · Molecular diagnostics / cell-free DNA testing
Natera uses proprietary blood-based cell-free DNA technology to deliver personalized genetic diagnostics for oncology, prenatal screening, and organ transplant health.
What Natera does
Natera is a molecular diagnostics company that develops and commercializes blood-based cell-free DNA (cfDNA) tests across three main healthcare areas: oncology, women's health, and organ health. The company uses proprietary molecular biology and bioinformatics technology to detect genetic variations from tiny amounts of circulating DNA in blood samples. Its test suite includes personalized cancer monitoring (Signatera), prenatal screening and hereditary cancer assessment (Panorama, Horizon), and transplant/organ rejection diagnostics, with over 3.5 million tests processed annually through direct sales and a global network of 100+ laboratory partners.
Themes: ["Liquid biopsy / circulating tumor DNA","Prenatal screening / women's health","Hereditary cancer screening","Transplant rejection monitoring","Personalized medicine / genomic diagnostics"]
Fundamentals
- Price$281.85 as of 2026-07-09 close
- Market cap$40.2B as of 2026-07-10
- 1-year return+74.3% as of 2026-07-09 close
- Net margin-9.1% as of 2026-07-10
- Gross margin+65.1% as of 2026-07-10
- ROE-15.1% as of 2026-07-10
- Debt / equity0.05 as of 2026-07-10
- Revenue growth (YoY)+36.6% as of 2026-07-10
- Revenue CAGR (3y)+41.1% SEC XBRL
- Beta1.54 as of 2026-07-10
Key risks (from latest filing)
["Reimbursement challenges: dependence on third-party payer coverage and reimbursement determinations for continued revenue growth, particularly for newer applications like Panorama microdeletion screening","Regulatory and compliance risk: need to maintain federal, state, and foreign regulatory compliance for laboratory operations and diagnostic testing; exposure to litigation and regulatory proceedings","Supply chain dependency: reliance on a limited number of suppliers including sole-source suppliers for laboratory instruments and materials, which could disrupt test availability and operational scaling"]
Competitors & peers
- Illumina (ILMN)
- Invitae (NVTA)
- Exact Sciences (EXAS)
- LabCorp (LH)
- Quest Diagnostics (DGX)
- Myriad Genetics (MYRG)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.